Nutriventia’s low dose turmeric extract launches in Blackmores
TurmXTRA is a low dose (250 mg curcuminoids) turmeric extract and can support joint and muscle health. A flagship branded ingredient by Nutriventia, it will be incorporated into a range of products by Blackmores.
“TurmXTRA's inclusion in Blackmores' products validates our philosophy of delivering high-quality, clinically proven ingredients to our customers, especially a brand with high standards for excellent such as Blackmores,” said Vishal Shah, Nutriventia’s co-founder and executive director.
Rajat Shah, Nutriventia co-founder, added that Blackmores is one of the largest supplement companies in the APAC region. The company has focused on high-quality science substantiating its products in terms of validation from supporting clinical trials and regulatory outlook as well as perception, she said.
“Partnering with such a credible and globally recognized brand enhances our market credibility and creates vast opportunities for TurmXTRA,” Rajat said. “This partnership allows us to reach a wider global audience, as Blackmores has a substantial market presence in various countries.”
The science
TurmXTRA is a proprietary water-dispersible turmeric extract in which a human clinical study demonstrated TurmXTRA’s superior bioavailability, showing bioequivalence from a single 250 mg once daily dose when compared to another branded turmeric extract with piperine, commonly consumed in three 500 mg doses.
These findings highlight TurmXTRA's efficiency and potency at a 250mg once daily dose which is also substantiated from the earlier clinical trials which showed benefits in healthy human subjects, positioning it as ingredient of choice for turmeric supplementation in all applications, Rajat said.
Scientists began working on creating TurmXTRA in 2016 and were able to launch the ingredient in 2022, supported by multiple pharmacokinetic studies. Since launching, Nutriventia has built a library of clinical substantiation, which now stands at three human clinical trials and three human pharmacokinetic studies and several preclinical and in-vitro studies.
“We aimed to develop a bioavailable ingredient with 20% curcuminoids, but this involved using synthetic excipients,” Rajat said. “Realizing this didn't align with our core values, we embarked on a longer journey to eliminate synthetics while maintaining bioavailability. This effort resulted in an ingredient with 60% active content, reducing the dose to 250mg with 150mg of bioavailable curcuminoids. This innovation set the benchmark for our subsequent developments.”
TurmXTRA does not use chemical surfactants or black pepper for enhancing absorption, and consumption has not shown any major adverse effects as demonstrated from the clinical trials and pharmacokinetic studies in humans.
Additionally, establishing TurmXTRA at a low dose is a significant breakthrough by Nutriventia in the joint and muscle health space because it is now possible to combine turmeric extract with other players in the space such as glucosamine and collagen with no significant increase in the number of tablets consumed, Rajat added.
“This creates an attractive value add since both products have distinct mechanisms of action and together provide synergistic effects to support joint health,” she said.
